| Physiologically Based Pharmacokinetic Modeling in Regulatory Science: An Update From the US Food and Drug Administration's Office of Clinical Pharmacology |
43 |
| Formulation of 3D Printed Tablet for Rapid Drug Release by Fused Deposition Modeling: Screening Polymers for Drug Release, Drug-Polymer Miscibility and Printability |
38 |
| Surfactant Effects on Lipid-Based Vesicles Properties |
30 |
| Role of Cyclodextrins in Nanoparticle-Based Drug Delivery Systems |
24 |
| Roadmap to 3D-Printed Oral Pharmaceutical Dosage Forms: Feedstock Filament Properties and Characterization for Fused Deposition Modeling |
24 |
| Physiologically Based Pharmacokinetic Modeling of Nanoparticles |
23 |
| The Importance of Understanding the Freezing Step and Its Impact on Freeze-Drying Process Performance |
21 |
| The Application of 3D Printing in the Formulation of Multilayered Fast Dissolving Oral Films |
19 |
| PTL a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers |
18 |
| Pediatric Oral Formulations: An Updated Review of Commercially Available Pediatric Oral Formulations Since 2007 |
18 |
| The Potential of Exosomes From Cow Milk for Oral Delivery |
17 |
| An Assessment of the Ability of Submicron- and Micron-Size Silicone Oil Droplets in Dropped Prefillable Syringes to Invoke Early- and Late-Stage Immune Responses |
16 |
| Nanostructured Lipid Carriers for Oral Bioavailability Enhancement of Exemestane: Formulation Design, In Vitro, Ex Vivo, and In Vivo Studies |
16 |
| Enhancing Tumor Drug Distribution With Ultrasound-Triggered Nanobubbles |
14 |
| Immunogenicity of Protein Pharmaceuticals |
14 |
| Factors Influencing Polysorbate's Sensitivity Against Enzymatic Hydrolysis and Oxidative Degradation |
14 |
| Deep Convolutional Neural Network Analysis of Flow Imaging Microscopy Data to Classify Subvisible Particles in Protein Formulations |
13 |
| Food Effect Projections via Physiologically Based Pharmacokinetic Modeling: Predictive Case Studies |
13 |
| Understanding the Differences Between Cocrystal and Salt Aqueous Solubilities |
13 |
| Predicting Solubility/Miscibility in Amorphous Dispersions: It Is Time to Move Beyond Regular Solution Theories |
12 |
| Development of Solid Dispersion by Hot Melt Extrusion Using Mixtures of Polyoxylglycerides With Polymers as Carriers for Increasing Dissolution Rate of a Poorly Soluble Drug Model |
12 |
| Selection of Solid-State Plasticizers as Processing Aids for Hot-Melt Extrusion |
12 |
| Direct Compression Tablet Containing 99% Active Ingredient-A Tale of Spherical Crystallization |
12 |
| Effects of Surfactants on Itraconazole-HPMCAS Solid Dispersion Prepared by Hot-Melt Extrusion I: Miscibility and Drug Release |
12 |
| Applications of Powder X-Ray Diffraction in Small Molecule Pharmaceuticals: Achievements and Aspirations |
12 |
| The Mechanistic Impact of N-Glycosylation on Stability, Pharmacokinetics, and Immunogenicity of Therapeutic Proteins |
11 |
| y Optimization of Nanostructured Lipid Carriers of Lurasidone Hydrochloride Using Box-Behnken Design for Brain Targeting: In Vitro and In Vivo Studies |
11 |
| Industry's View on Using Quality Control, Biorelevant, and Clinically Relevant Dissolution Tests for Pharmaceutical Development, Registration, and Commercialization |
11 |
| The Combination of GIS and Biphasic to Better Predict In Vivo Dissolution of BCS Class IIb Drugs, Ketoconazole and Raloxifene |
11 |
| Dual-Targeting Nanoparticles: Codelivery of Curcumin and 5-Fluorouracil for Synergistic Treatment of Hepatocarcinoma |
11 |
| Application of the Quality by Design Approach to the Freezing Step of Freeze-Drying: Building the Design Space |
10 |
| Improved Stability of Tuberculosis Drug Fixed-Dose Combination Using Isoniazid-Caffeic Acid and Vanillic Acid Cocrystal |
10 |
| Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins |
10 |
| Preservative and Irritant Capacity of Biosurfactants From Different Sources: A Comparative Study |
10 |
| Are Injection Site Reactions in Monoclonal Antibody Therapies Caused by Polysorbate Excipient Degradants? |
10 |
| Dysregulation of Mucosal Membrane Transporters and Drug-Metabolizing Enzymes in Ulcerative Colitis |
10 |
| Composite Alginate-Hyaluronan Sponges for the Delivery of Tranexamic Acid in Postextractive Alveolar Wounds |
10 |
| Submicron Size Particles of a Murine Monoclonal Antibody Are More Immunogenic Than Soluble Oligomers or Micron Size Particles Upon Subcutaneous Administration in Mice |
10 |
| Impact of Different Dry and Wet Granulation Techniques on Granule and Tablet Properties: A Comparative Study |
10 |
| Application of a Dynamic Fluid and pH Model to Simulate Intraluminal and Systemic Concentrations of a Weak Base in GastroPlus (TM) |
10 |
| Effect of Controlled Ice Nucleation on Stability of Lactate Dehydrogenase During Freeze-Drying |
9 |
| Biopharmaceutic IVIVE-Mechanistic Modeling of Single- and Two-Phase In Vitro Experiments to Obtain Drug-Specific Parameters for Incorporation Into PBPK Models |
9 |
| Chitosan-Gelatin Hydrogel Crosslinked With Oxidized Sucrose for the Ocular Delivery of Timolol Maleate |
9 |
| Critical Evaluation of Microfluidic Resistive Pulse Sensing for Quantification and Sizing of Nanometer- and Micrometer-Sized Particles in Biopharmaceutical Products |
9 |
| Dissolving Microneedles Loaded With Etonogestrel Microcrystal Particles for Intradermal Sustained Delivery |
9 |
| Dose Optimization of Chloroquine by Pharmacokinetic Modeling During Pregnancy for the Treatment of Zika Virus Infection |
9 |
| Superparamagnetic Iron Oxidee-Loaded Lipid Nanocarriers Incorporated in Thermosensitive In Situ Gel for Magnetic Brain Targeting of Clonazepam |
9 |
| Albumin-Encapsulated Liposomes: A Novel Drug Delivery Carrier With Hydrophobic Drugs Encapsulated in the Inner Aqueous Core |
9 |
| Developing Quantitative In Vitro-In Vivo Correlation for Fenofibrate Immediate-Release Formulations With the Biphasic Dissolution-Partition Test Method |
9 |
| Population Pharmacokinetic and Exposure-Response Analyses of Baloxavir Marboxil in Adults and Adolescents Including Patients With Influenza |
9 |
